Analyst Ratings for Bicara Therapeutics Inc (BCAX)
BCAX Rating Summary
BCAX Price Target Summary
- Highest: $48.00 (Stifel)
- Lowest: $11.00 (Wells Fargo)
- Average: $27.56
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$27.56 (+49.2%)
* Over Last 12-Mos
Rating Score: 7.9 / 10
Percentile Rank: 83%
Avg. $ Target:
$27.56 (+49.2%)
* Over Last 12-Mos
Rating Score: 7.9 / 10
Percentile Rank: 83%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/11/2026 | Goldman Sachs | Richard Law | Downgrade | Neutral (Buy) |
14.00 (N/A) |
14.97 (18.47) |
23.38% | Details |
| 1/29/2026 | Citizens » Updated 2/23/2026 |
Reni Benjamin | New Coverage | Market Outperform (N/A) |
31.00 (N/A) |
16.77 (18.47) |
10.14% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
